Upload
Featured Recent Articles Topics Login Upload

Search Results for 'hcv rbv'

hcv rbv published presentations and documents on DocSlides.

PEG alfa-2a RBV versus
PEG alfa-2a RBV versus
by alexa-scheidler
. PEG alfa-. 2a . versus. INF RBV . APRICOT S...
Daclatasvir + Sofosbuvir + RBV in GT3
Daclatasvir + Sofosbuvir + RBV in GT3
by sophia2
. with Advanced Liver Disease. ALLY-3+ Study. Phas...
HCV Clinical Management TRAINER(S)
HCV Clinical Management TRAINER(S)
by trish-goza
IAPAC African Regional Capacity-Building Hub. Bas...
HCV Clinical Management TRAINER(S)
HCV Clinical Management TRAINER(S)
by danika-pritchard
IAPAC African Regional Capacity-Building Hub. Bas...
Prevention strategies for HIV/HCV co infection
Prevention strategies for HIV/HCV co infection
by giovanna-bartolotta
Isabelle Andrieux-Meyer, MD. Médecins Sans Front...
Future HCV Treatment Paradigms
Future HCV Treatment Paradigms
by kittie-lecroy
Mark Sulkowski, MD . Professor of Medicine. Medic...
Direct Acting Antivirals: What are they? What is their pl
Direct Acting Antivirals: What are they? What is their pl
by tawny-fly
Mark Sulkowski, MD. Associate Professor of Medici...
Current strategies for the management of treatment naïve a
Current strategies for the management of treatment naïve a
by min-jolicoeur
Mark S. Sulkowski, MD. Medical Director, Viral He...
TURQUOISE-I
TURQUOISE-I
by natalia-silvester
OBV/PTV/r + . DSV . + RBV. OBV/PTV/r + . DSV . + ...
HIV and HCV Update for the Pharmacist – June 2014
HIV and HCV Update for the Pharmacist – June 2014
by marina-yarberry
John J. . Faragon. , . PharmD. , BCPS, AAHIV-P. R...
Edited by
Edited by
by celsa-spraggs
Morris Sherman MD . BCh. PhD FRCP(C) . Associate...
Out With the Old and In With the New, Again?
Out With the Old and In With the New, Again?
by test
Out With the Old, In With the New. Current Standa...
Hepatitis C Drug Pipeline
Hepatitis C Drug Pipeline
by cheryl-pisano
HCV WORLD CAB .  FEBRUARY 2014. BANGKOK, THAI...
TURQUOISE-I
TURQUOISE-I
by marina-yarberry
OBV/PTV/r + . DSV . + RBV. OBV/PTV/r + . DSV . + ...
PEG alfa-2a +
PEG alfa-2a +
by tawny-fly
RBV . versus. . PEG alfa-. 2a . versus. INF + R...
Peginterferon alfa-2a +
Peginterferon alfa-2a +
by stefany-barnette
RBV . versus. Interferon alfa. -. 2a + RBV . ACT...
OBV/PTV/r DSV RBV OBV/PTV/r
OBV/PTV/r DSV RBV OBV/PTV/r
by ellena-manuel
DSV . placebo. Randomisation*. Partial blind. 1...
FISSION Design Objective
FISSION Design Objective
by travis
Non . inferiority. of SOF + RBV : SVR. 12. (. 2-...
Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care
Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care
by lois-ondreau
Sameh W. Boktor, MD, MPH. Medical Epidemiologist....
Updates in Treatment of Hepatitis C
Updates in Treatment of Hepatitis C
by cheryl-pisano
Gene LeSage, MD, FACP, AGAF. Objectives. HCV epid...
Updates in Treatment of Hepatitis C
Updates in Treatment of Hepatitis C
by myesha-ticknor
Gene LeSage, MD, FACP, AGAF. Objectives. HCV epid...
Hepatitis C Imtiaz Alam, M.D.
Hepatitis C Imtiaz Alam, M.D.
by olivia-moreira
Medical Director, Austin Hepatitis Center. 1. Hep...
Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care
Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care
by webraph
Sameh W. Boktor, MD, MPH. Medical Epidemiologist. ...
SAPPHIRE-I
SAPPHIRE-I
by ellena-manuel
Feld JJ. NEJM . 2014;370:1594-1603. SAPPHIRE-I . ...
Use of HCV DAAs with HIV Regimens
Use of HCV DAAs with HIV Regimens
by robaut
Sam Lam, . PharmD. Annie Vong, . PharmD. 2/3/2017....
Update on the HCV Antiviral Pipeline
Update on the HCV Antiviral Pipeline
by natalia-silvester
Todd S. Wills, MD. SPNS HCV Treatment Expansion I...
Management of HCV in Co-Infected Patients
Management of HCV in Co-Infected Patients
by danika-pritchard
Marie-Louise Vachon, MD, . MSc. Division of . Inf...
HIV-HCV Coinfection in the era of effective antiviral therapy
HIV-HCV Coinfection in the era of effective antiviral therapy
by mia
Mark Sulkowski, . MD. Professor of Medicine. Medic...
EASL 2019 HCV Conference Update
EASL 2019 HCV Conference Update
by sophia
April 10. –14. , 2019. Vienna, Austria. Disclaim...
SOF/VEL
SOF/VEL
by trish-goza
400/100 mg . qd. N = 120. N = 120. W12. SOF + RBV...
SIRIUS
SIRIUS
by tawny-fly
Placebo. LDV/SOF + placebo. Randomisation*. 1 : 1...
C-SCAPE
C-SCAPE
by pasty-toler
Design. C-SCAPE . Study. : . grazoprevir. ± . e...
3 D (Paritaprevir
3 D (Paritaprevir
by myesha-ticknor
-Ritonavir. -Ombitasvir . + Dasabuvir) . + RBV in...
State of the Art Therapy for HCV
State of the Art Therapy for HCV
by liane-varnes
Last Updated: February . 21, 2014. Robert G. Gish...
Dore G. J
Dore G. J
by pasty-toler
Hepatol. 2016; 64:19-28. MALACHITE. TVR + PEG-IF...
C-SCAPE
C-SCAPE
by tawny-fly
Design. C-SCAPE . Study. : . grazoprevir. ± . e...
Dore G. J
Dore G. J
by myesha-ticknor
Hepatol. 2016; 64:19-28. MALACHITE. TVR + PEG-IF...
OBV/PTV/r DSV Open label
OBV/PTV/r DSV Open label
by kittie-lecroy
≥ 18 years. Chronic HCV infection. Genotype 1. ...
Chronic hepatitis C: guidelines for screening and
Chronic hepatitis C: guidelines for screening and
by aaron
treatment. Lisa M. Glass, MD. Clinical Lecturer. ...
Updated Guidelines for Managing HIV/HCV Co-Infection
Updated Guidelines for Managing HIV/HCV Co-Infection
by karlyn-bohler
John J . Faragon. , . PharmD. , BCPS, AAHIV-P. Re...